MedTrace Logo

Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia

NCT01696383 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2013-02-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5%) from prior prostaglandin analogue or beta-blocker monotherapy in Russian glaucoma patients with open-angle glaucoma or ocular hypertension whose intraocular pressure (IOP) is uncontrolled while on their current treatment.

Conditions

Interventions

DRUG

Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)

One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Abayomi Ogundele, PharmD · Alcon Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-28
Primary Completion
2013-02-28
Completion
2013-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01696383 on ClinicalTrials.gov